Signifier® Medical Technologies Hosted a Global Webinar on: “Latest Advances in the Management of Sleep Disordered Breathing”
LONDON, 17th July 2020
Signifier Medical Technologies, an innovator in the sleep disordered breathing market, recently hosted a global webinar with leading world experts in the field of sleep disordered breathing (SDB).
The webinar was centred on “Precision medicine for obstructive sleep apnea and emerging technologies” and it was hosted by Prof. Dr. Peter Cistulli (ResMed Chair in Sleep Medicine at the University of Sydney, Australia) and Prof. Dr. Atul Malhotra, (Research Chief in Pulmonary, Critical Care and Sleep Medicine at UC San Diego, USA).
Prof. Dr. Anshul Sama (Consultant ENT and Sleep Physician at Nottingham University Hospital, UK and inventor of the daytime intraoral neuromuscular electrical stimulation (NMES) technology1-2 for reduction of sleep disordered breathing) also participated to the webinar presenting the Snoozeal® technology and the new treatment proposed with the Snoozeal® device.
The webinar shed new light on the SDB space and presented novel clinical data on the new NMES technology associated with Snoozeal®.
This new data brought together results from a multi-centre clinical study held in tier-1 academic centres at London Teaching Hospital and Spain (University of Navarra) – with c. 115 participants.
The clinical results showed:
- Significant clinical reductions in objective mild Obstructive Sleep Apnea (OSA) indexes, including AHI, ODI and RDI; and
- Subjective questionnaires completed by bed partners that reported a substantial reduction in snoring.
This treatment resulted in an improved quality of sleep for both the patients and their partner3.
Snoozeal® is a non-invasive daytime therapy for the tongue which delivers small contractions that improves muscle function and reduces the physiological collapse of the tongue during sleep. The device is a one size fits all and effective when used for 20 minutes a day for six weeks, with sustained improvement with minimal weekly maintenance.
Patients often find conventional night-time solutions ineffective or difficult to tolerate. With the increasing public and digital awareness of sleep and sleep devices, it is increasingly likely that more patients will be consulting their healthcare professionals on these issues.
Snoozeal® gives healthcare professionals and patients an effective solution that is easy and convenient to use.
If you missed it live, visit www.snoozeal.com/past-webinars to view previous webinars on-demand and register for future webinars.
About Snoring and OSA
Nearly 1 billion adults aged 30 to 69 are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between obstructive sleep apnea and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.
Obstructive sleep apnea is marked by recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.
Standard therapy of all advanced levels of sleep apnea is with a continuous positive airway pressure (CPAP) device. Many patients find this therapy invasive, and the long-term compliance of CPAP therapy is limited, so there is a demand for new forms of treatment.
About Signifier Medical Technologies
Signifier Medical Technologies, previously known as Snoozeal, is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with snoring and sleep disordered breathing conditions. Signifier’s proprietary therapy is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology, with proven clinical data from prestigious and well-recognised universities and academic institutions, that provides a safe and effective treatment for its patients.1-3
- Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.
- Sama A, et al. Daytime Intraoral Neurostimulation with Snoozeal® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.
- Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI <15). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period
For media enquiries:
+44 (0) 207 096 0586